Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2010 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Poster Presentation Details

Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis

  • Presenter: Greg Coffey, Ph.D., Portola Pharmaceuticals
  • Poster Session: Lymphocytes, Lymphocyte Activation and Immunodeficiency, Including HIV and Other Infections: Poster I
  • Date: Saturday, December 4, 5:30 - 7:30 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board I-707

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity in Primary CLL Cells and is Synergistic with Fludarabine at Low Concentrations

  • Presenter: Stephen Spurgeon, M.D., Oregon Health & Science University Knight Cancer Institute
  • Poster Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
  • Date: Sunday, December 5, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board II-719

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

  • Presenter: Jan Burger, M.D., Ph.D., MD Anderson Cancer Center
  • Poster Session: CLL - Biology and Pathophysiology, excluding Therapy: Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

  • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
  • Poster Session: Pathophysiology of Thrombosis: Poster II
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-997

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade;  PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis  and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.  It is a part of our broader program based on novel Syk and JAK inhibitors to treat additional inflammatory disease and oncology. For additional information, visit www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
11. Onyx Pharmaceuticals Announces December 2010 Investor Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today ... 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical ... behavioral health analytics to improve Medicaid population health management. , ODH will also have ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could ... in the United States may be taken over by technology in the next five ... steamrolls over colleagues is drawing to a close. Success will belong to those who ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... 2017 , ... The Radiology Business Management Association will select the ... annual Building Better Radiology Marketing Programs conference, held this year from March ... Nine awards are given out in five categories. They are:, , ...
Breaking Medicine News(10 mins):